NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agios Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $43.30 -0.81 (-1.84 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$43.09Now: $43.30▼$44.3750-Day Range$45.32MA: $51.36▼$55.9352-Week Range$27.77Now: $43.30▼$56.74Volume623,225 shsAverage Volume694,495 shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $69.83, Agios Pharmaceuticals has a potential upside of 61.3% from its current price of $43.30.Amount of Analyst CoverageAgios Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesAgios Pharmaceuticals has received 447 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAgios Pharmaceuticals has received 373 “underperform” votes. (Add your “underperform” vote.)Community SentimentAgios Pharmaceuticals has received 54.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote “Outperform” if you believe AGIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $179,186.00 in company stock.Percentage Held by InsidersOnly 3.16% of the stock of Agios Pharmaceuticals is held by insiders.Percentage Held by Institutions97.73% of the stock of Agios Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($4.53) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -8.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -8.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO Previous Symbol CUSIPN/A CIK1439222 Webwww.agios.com Phone617-649-8600Debt Debt-to-Equity Ratio0.18 Current Ratio13.15 Quick Ratio12.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$117.91 million Price / Sales25.38 Cash FlowN/A Price / Cash FlowN/A Book Value$8.08 per share Price / Book5.36Profitability EPS (Most Recent Fiscal Year)($6.86) Net Income$-411,470,000.00 Net Margins-182.49% Return on Equity-59.71% Return on Assets-40.33%Miscellaneous Employees482 Outstanding Shares69,110,000Market Cap$2.99 billion Next Earnings Date10/29/2020 (Estimated) OptionableOptionable $43.30 -0.81 (-1.84 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AGIO News and Ratings via Email Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO stock has increased by 5.9% and is now trading at $43.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals. When is Agios Pharmaceuticals' next earnings date? Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020. View our earnings forecast for Agios Pharmaceuticals. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.36) by $0.05. The biopharmaceutical company had revenue of $37.30 million for the quarter, compared to analyst estimates of $37.17 million. Agios Pharmaceuticals had a negative return on equity of 59.71% and a negative net margin of 182.49%. Agios Pharmaceuticals's revenue for the quarter was up 42.4% compared to the same quarter last year. During the same period last year, the business posted ($1.87) EPS. View Agios Pharmaceuticals' earnings history. What price target have analysts set for AGIO? 14 brokerages have issued 12 month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $69.83 in the next twelve months. This suggests a possible upside of 61.3% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals. Has Agios Pharmaceuticals been receiving favorable news coverage? News coverage about AGIO stock has trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Agios Pharmaceuticals. Who are some of Agios Pharmaceuticals' key competitors? Some companies that are related to Agios Pharmaceuticals include Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals (ACAD), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR) and Reata Pharmaceuticals (RETA). View all competitors. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU) and NVIDIA (NVDA). Who are Agios Pharmaceuticals' key executives? Agios Pharmaceuticals' management team includes the following people: Jacqualyn A. Fouse, Chief Executive Officer & DirectorAndrew J. Hirsch, CFO & Head-Corporate DevelopmentScott Biller, Chief Scientific OfficerChris Bowden, Chief Medical OfficerClive Patience, Senior Vice President-Technical Operations What is Agios Pharmaceuticals' stock symbol? Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO." Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.31%), Peregrine Capital Management LLC (0.26%), ZWJ Investment Counsel Inc. (0.25%), Swiss National Bank (0.20%), Rhenman & Partners Asset Management AB (0.13%) and Assenagon Asset Management S.A. (0.07%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Scott Biller and Steven L Hoerter. View institutional ownership trends for Agios Pharmaceuticals. Which major investors are selling Agios Pharmaceuticals stock? AGIO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Rhenman & Partners Asset Management AB, Cutler Group LP, Virtus ETF Advisers LLC, Carroll Financial Associates Inc., and Arizona State Retirement System. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden. View insider buying and selling activity for Agios Pharmaceuticals. Which major investors are buying Agios Pharmaceuticals stock? AGIO stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Peregrine Capital Management LLC, Assenagon Asset Management S.A., Russell Investments Group Ltd., WINTON GROUP Ltd, Swiss National Bank, ZWJ Investment Counsel Inc., and AE Wealth Management LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse. View insider buying and selling activity for Agios Pharmaceuticals. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Agios Pharmaceuticals' stock price today? One share of AGIO stock can currently be purchased for approximately $43.30. How big of a company is Agios Pharmaceuticals? Agios Pharmaceuticals has a market capitalization of $2.99 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe. What is Agios Pharmaceuticals' official website? The official website for Agios Pharmaceuticals is www.agios.com. How can I contact Agios Pharmaceuticals? Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
